GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Policyholder Funds

Hyloris Pharmaceuticals (LTS:0AB6) Policyholder Funds


View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Policyholder Funds?

Policyholder Funds only applies to insurance companies.


Hyloris Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.